Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Dow
Merck
Medtronic
Johnson and Johnson

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Litigation Details for MERCK SHARP & DOHME CORP. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2015)

See Plans and Pricing

« Back to Dashboard

MERCK SHARP & DOHME CORP. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2015)

Docket   Start Trial Date Filed 2015-08-06
Court District Court, D. New Jersey Date Terminated 2017-09-29
Cause 35:271 Patent Infringement Assigned To Peter G. Sheridan
Jury Demand None Referred To
Parties ACTAVIS LABORATORIES FL, INC.; ACTAVIS PHARMA, INC.; ACTAVIS, INC.; ANDRX CORPORATION; MERCK SHARP & DOHME CORP.
Patents 4,282,233; 4,659,716; 5,661,151
Attorneys CHARLES H. CHEVALIER; CHRISTINE A. GADDIS; DAVID E. DELORENZI; LIZA M. WALSH; SELINA MIRIAM ELLIS; TRICIA B. O'REILLY
Link to Docket External link to docket
Small Molecule Drugs cited in MERCK SHARP & DOHME CORP. v. ACTAVIS LABORATORIES FL, INC.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for MERCK SHARP & DOHME CORP. v. ACTAVIS LABORATORIES FL, INC. (D.N.J. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-08-06 1 is an action for patent infringement of U.S. Patent No. 5,661,151 (the “’151 Patent”), arising under… COUNT 1: INFRINGEMENT OF U.S. PATENT 5,661,151 25. Merck incorporates…one or more of the claims of the ’151 Patent. The ’151 Patent is listed in the FDA’s Approved Drug Products…the term of the ’151 Patent, Defendants would further infringe the ’151 Patent under 35 U.S.C. §§ 271… Defendants. COMPLAINT FOR PATENT INFRINGEMENT Case 3:15-cv-06075-PGS-DEA Document External link to document
2017-01-23 104 Anticipation Defense to Claim 12 of U.S. Patent No. 5,661,151 (Attachments: # 1 Responsive Statement of… 29 September 2017 3:15-cv-06075 830 Patent None District Court, D. New Jersey External link to document
2017-01-24 105 Anticipation Defense to Claim 12 of U.S. Patent No. 5,661,151 (Attachments: # 1 Responsive Statement of… 29 September 2017 3:15-cv-06075 830 Patent None District Court, D. New Jersey External link to document
2017-01-30 109 Anticipation Defense to Claim 12 of U.S. Patent No. 5,661,151 ; re [104, 105] BRIEF in Opposition filed… 29 September 2017 3:15-cv-06075 830 Patent None District Court, D. New Jersey External link to document
2017-02-10 114 if the asserted claims of U.S. Patent No. 5,661,151 (“the ’151 patent”) are found valid and enforceable…(1) the Teva Defendants launch at risk; (2) the patent- in-suit is held not invalid; and (3) the Teva… ANDA Product before the expiration of the ’151 patent, or induce or contribute to any such conduct…full compensation from the Teva entities if the patent-in- suit was held not invalid. But such a …Page 13 of 18 PageID: 2076 approval until patent expiration, or injunctive relief precluding commercialization External link to document
2017-03-06 118 Pat. 4,282,233 (the “’ 233 patent”) infringed claims 1 and 3 of the 4,659,716 (the “’716 patent”), which…U.S. Pat. 5,661,151 (the “’151 patent”) (see Dkt. No. 89). The ’151 patent is directed to synthesis and…BACKGROUND I. The ’151 Patent The ’151 patent, entitled “Tetrahydrofuran Antifungals… abstract of the ’151 patent). In its background section, the ’151 patent cites to prior art reference…, citing the ’151 patent, col. 2:10-17; Dkt. No. 89-4). The ’151 patent discloses that compounds External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
Express Scripts
Baxter
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.